Open Funding Opportunities
FOA # | FOA Title | Research Focus Area | Earliest Submission Date | Expiration Date | Posted Date Sort ascending |
---|---|---|---|---|---|
NOT-HD-23-015 Show Summary |
Notice of Intent to Publish a Notice of Funding Opportunity for the HEAL Initiative: KIDS Acute Pain Clinical Trials (APCT) Program (U01 Clinical Trial Required) | Wed, 11/01/2023 | Wed, 11/01/2023 | Sat, 07/01/2023 | |
As part of the NIH’s Helping to End Addiction Long-term (HEAL) Initiative, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and participating NIH Institutes and Centers (ICs) intend to publish a Notice of Funding Opportunity (NOFO) to support research that aligns with one of the research goals of the NIH HEAL Initiative to support new clinical trial programs and the expansion of existing programs to evaluate innovative therapies for pain management. The HEAL KIDS (Knowledge, Innovation and Discovery Studies) Pain initiative will be comprised of interrelated programs addressing critical needs in pediatric pain research. This Notice of Intent to Publish announces plans to support the Acute Pain Clinical Trials (APCT) program, focusing on research to improve the assessment, management, and treatment of acute pain in pediatric patients in various health care settings through innovative multi-site clinical trials while integrating relevant behavioral and social influences and contexts on pain experience. |
|||||
NOT-HD-23-016 Show Summary |
Notice of Intent to Publish a Notice of Funding Opportunity for the HEAL Initiative: HEAL KIDS (Knowledge, Innovation and Discovery Studies) Pain Program Resource and Data Center (U24 Clinical Trial Not Allowed) | Wed, 11/01/2023 | Wed, 11/01/2023 | Sat, 07/01/2023 | |
As part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and participating NIH Institutes and Centers (ICs) intend to publish a Notice of Funding Opportunity (NOFO) to support research that aligns with one of the research goals of the NIH HEAL Initiative to support new clinical trial programs and the expansion of existing programs to evaluate innovative therapies for pain management. The HEAL KIDS (Knowledge, Innovation and Discovery Studies) Pain program will include interrelated programs addressing critical needs in pediatric pain research. This Notice of Intent to Publish announces plans to support the HEAL KIDS Pain Resource and Data Center (RDC) which will provide the following: leadership in data curation and data harmonization; leveraging relevant data standards; administrative and logistical support including oversight of NIH HEAL-related requirements; and coordination of shared research-related resources for the HEAL KIDS Pain research activities and HEAL-compliant data registries. |
|||||
RFA-NS-24-015 Show Summary |
HEAL Initiative Partnerships to Advance INterdisciplinary (PAIN) Training in Clinical Pain Research: The HEAL PAIN Cohort Program (T90/R90 Independent Clinical Trial Not Allowed) | Clinical Research in Pain Management | Sat, 08/26/2023 | Wed, 09/27/2023 | Tue, 05/09/2023 |
To bolster the dwindling clinical pain research workforce, the NIH HEAL Initiative® Partnership to Advance INterdisciplinary (PAIN) Training in Clinical Pain Research (the HEAL PAIN Cohort Program) will support interdisciplinary postdoctoral training to promote the next generation of independent clinical pain researchers. |
|||||
RFA-NS-23-028 Show Summary |
HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional) | Preclinical and Translational Research in Pain Management | Sat, 05/13/2023 | Tue, 06/10/2025 | Thu, 04/27/2023 |
Through targeted research efforts, the NIH HEAL Initiative aims to support the development of safe and effective devices to treat pain with little or no addiction liability. This notice of funding opportunity (NOFO) is designed to support interdisciplinary research teams of multiple PDs/PIs to investigate the mechanisms of action of pain relief using FDA-approved or -cleared medical devices with the overall goal of optimizing therapeutic outcomes for these technologies. Program teams are expected to accomplish goals that require considerable synergy and collaborative interactions. Teams must leverage appropriate multi-disciplinary expertise to develop new principles and methods for experimentation, analysis, and interpretation. Project goals should not be achievable with a collection of individual efforts or projects. Teams are encouraged to consider objectives that will produce major advances in the understanding of pain relief by medical devices that are likely to improve strategies for pain management. |
|||||
OTA-23-005 | HEAL Initiative: EPPIC-Net Pain Research Asset Application – Dossier (OT2) | Clinical Research in Pain Management | Thu, 04/20/2023 | Sat, 04/20/2024 | Thu, 04/20/2023 |
no summary
|
|||||
OTA-23-006 | HEAL Initiative: EPPIC-Net Pain Research – Protocol Application for Clinical Trial and Related Activities (OT2) | Clinical Research in Pain Management | Sat, 04/20/2024 | Thu, 04/20/2023 | |
no summary
|
|||||
RFA-NS-24-018 | HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional) | Clinical Research in Pain Management | Wed, 05/10/2023 | Tue, 10/24/2023 | Thu, 02/16/2023 |
no summary
|
|||||
PAR-23-069 Show Summary |
HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed) | Preclinical and Translational Research in Pain Management | Sun, 03/05/2023 | Sat, 09/06/2025 | Tue, 01/03/2023 |
The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the transition of previously funded SBIR and STTR Phase II and Phase IIB projects in pain management to the commercialization stage by providing additional assistance for private partnering activities through the Commercialization Readiness Pilot (CRP) program. Specifically, this FOA supports the addition of entrepreneurial expertise into small business leadership teams along with supporting partnering activities to aid in commercialization through private third-party funding or partnership with industry. Clinical trials are not accepted under this FOA. |
|||||
RFA-NS-22-024 Show Summary |
HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity (K99/R00 Independent Basic Experimental Studies with Humans Required) | Cross-Cutting Research | Tue, 01/10/2023 | Wed, 03/12/2025 | Thu, 12/15/2022 |
The purpose of this NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trained, independent investigators from diverse backgrounds (e.g. see NOT-OD-20-031, Notice of NIH’s Interest in Diversity) conducting Pain and/or SUD research, in order to promote a diverse pool of available independent investigators working in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. |
|||||
RFA-NS-22-022 Show Summary |
HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (K99/R00 Independent Clinical Trial Not Allowed) | Cross-Cutting Research | Tue, 01/10/2023 | Wed, 03/12/2025 | Thu, 12/15/2022 |
The purpose of the NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trainedindependent investigators conducting Pain and/or SUD research, in order to increase the independent investigator workforce in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, an ancillary study to a clinical trial, or an independent Basic Experimental Studies with Humans (BESH). Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing an independent BESH as lead investigator, should apply to the companion FOA (RFA-NS-22-023). |
|||||
RFA-NS-22-023 Show Summary |
HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (Independent Basic Experimental Studies with Humans Required) | Cross-Cutting Research | Tue, 01/10/2023 | Wed, 03/12/2025 | Thu, 12/15/2022 |
The purpose of the NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trained independent investigators conducting Pain and/or SUD research, in order to increase the independent investigator workforce in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. |
|||||
RFA-NS-22-069 | HEAL Initiative Integrated Basic and Clinical Team-based Research in Pain (RM1 Clinical Trial Optional) | Clinical Research in Pain Management, Preclinical and Translational Research in Pain Management | Sat, 01/14/2023 | Tue, 03/12/2024 | Fri, 11/04/2022 |
no summary
|
|||||
NOT-DA-23-009 | Notice of Special Interest (NOSI): HEAL Initiative: Grand Opportunity in Medications Development for Substance-Use Disorders | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Thu, 10/27/2022 | Tue, 09/02/2025 | Thu, 09/29/2022 |
no summary
|
|||||
NOT-DA-23-010 | Notice of Special Interest (NOSI): HEAL Initiative: Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Thu, 10/27/2022 | Tue, 09/02/2025 | Wed, 09/28/2022 |
no summary
|
|||||
RFA-NS-23-006 | HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed) | Cross-Cutting Research | Sun, 12/04/2022 | Sat, 04/05/2025 | Thu, 09/15/2022 |
no summary
|
|||||
RFA-NS-23-007 | HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed) | Cross-Cutting Research | Sun, 12/04/2022 | Sat, 04/05/2025 | Thu, 09/15/2022 |
no summary
|
|||||
PAR-22-202 | Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional) | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Sat, 09/03/2022 | Tue, 09/02/2025 | Thu, 09/01/2022 |
no summary
|
|||||
PAR-22-200 | Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Sat, 09/03/2022 | Tue, 09/02/2025 | Thu, 09/01/2022 |
no summary
|
|||||
RFA-EB-22-002 | HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed) | Preclinical and Translational Research in Pain Management | Fri, 10/14/2022 | Wed, 06/18/2025 | Tue, 08/23/2022 |
no summary
|
|||||
NOT-DA-23-005 | Notice of Special Interest (NOSI): HEAL Initiative: Biospecimen Collection in Pregnancy | Enhanced Outcomes for Infants and Children Exposed to Opioids | Sun, 09/25/2022 | Sun, 10/08/2023 | Mon, 08/22/2022 |
no summary
|
|||||
RFA-NS-22-070 | HEAL Initiative: Development and Validation of Non-Rodent Mammalian Models of Pain (R01 Clinical Trial Not Allowed) | Preclinical and Translational Research in Pain Management | Tue, 10/04/2022 | Thu, 03/07/2024 | Tue, 08/09/2022 |
no summary
|
|||||
RFA-DA-23-054 | HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional) | Cross-Cutting Research | Fri, 10/14/2022 | Thu, 03/21/2024 | Wed, 08/03/2022 |
no summary
|
|||||
RFA-DA-23-053 | HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional) | Translation of Research to Practice for the Treatment of Opioid Addiction | Fri, 10/14/2022 | Thu, 03/21/2024 | Wed, 08/03/2022 |
no summary
|
|||||
NOT-NS-23-002 | Notice of Special Interest (NOSI): HEAL Initiative: Clinical Translation of Diagnostic and Therapeutic Devices via Blueprint MedTech | Preclinical and Translational Research in Pain Management | Tue, 10/18/2022 | Fri, 06/21/2024 | Wed, 08/03/2022 |
no summary
|
|||||
NOT-DA-23-007 | Notice of Special Interest (NOSI): HEAL Initiative: Opioid Use Disorder Care Pathways for Individuals with Histories of Exposure to Violence | Translation of Research to Practice for the Treatment of Opioid Addiction | Wed, 10/12/2022 | Sun, 07/13/2025 | Wed, 08/03/2022 |
no summary
|
|||||
NOT-NS-23-002 | Notice of Special Interest (NOSI): HEAL Initiative: Clinical Translation of Diagnostic and Therapeutic Devices via Blueprint MedTech | Preclinical and Translational Research in Pain Management | Tue, 10/18/2022 | Fri, 06/21/2024 | Wed, 08/03/2022 |
no summary
|
|||||
NOT-DA-23-008 | Notice of Special Interest (NOSI) HEAL Initiative: Workforce Interventions to Improve Addiction Care Quality and Patient Outcomes | Cross-Cutting Research | Wed, 10/05/2022 | Mon, 09/08/2025 | Wed, 08/03/2022 |
no summary
|
|||||
RFA-NS-23-003 | HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional) | Preclinical and Translational Research in Pain Management | Sat, 09/10/2022 | Tue, 06/10/2025 | Mon, 08/01/2022 |
no summary
|
|||||
NOT-NS-23-009 | Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative Integrated Basic and Clinical Team-based Research in Pain (RM1 Clinical Trial Optional) | Preclinical and Translational Research in Pain Management | Fri, 11/11/2022 | Sat, 07/01/2023 | Fri, 07/29/2022 |
no summary
|
|||||
PAS-22-207 | HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required) | Cross-Cutting Research | Mon, 09/12/2022 | Thu, 11/13/2025 | Thu, 07/14/2022 |
no summary
|
|||||
NOT-NS-22-095 | HEAL Initiative Notice of Special Interest (NOSI): Development and Validation of Pain-Related Models and Endpoints to Facilitate Non-Addictive Analgesic Discovery | Clinical Research in Pain Management | Tue, 10/18/2022 | Wed, 06/25/2025 | Thu, 07/14/2022 |
no summary
|
|||||
PAS-22-206 | HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required) | Cross-Cutting Research | Mon, 09/12/2022 | Thu, 11/13/2025 | Thu, 07/14/2022 |
no summary
|
|||||
NOT-NS-22-087 | Encourage Eligible NIH HEAL Initiative Awardees to Apply for Administrative Supplements to Support Career Enhancement Related to Clinical Research on Pain | Clinical Research in Pain Management | Mon, 06/20/2022 | Fri, 02/16/2024 | Mon, 06/06/2022 |
no summary
|
|||||
NOT-NS-22-049 | Notice of Early Termination of RFA-NS-21-015 "HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)" | Preclinical and Translational Research in Pain Management | Sat, 03/27/2021 | Wed, 10/11/2023 | Fri, 04/22/2022 |
no summary
|
|||||
RFA-NS-22-052 | HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed) | Preclinical and Translational Research in Pain Management | Mon, 05/09/2022 | Wed, 10/11/2023 | Fri, 04/22/2022 |
no summary
|
|||||
NOT-DA-22-056 | Notice of Special Interest (NOSI): Developing Digital Therapeutics for Substance Use Disorders | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Wed, 04/06/2022 | Thu, 12/07/2023 | Fri, 02/18/2022 |
no summary
|
|||||
NOT-DA-22-001 | Notice of Change to Key Dates for NIDA PAR-21-183, Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional) | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Sun, 07/04/2021 | Thu, 12/07/2023 | Sun, 02/06/2022 |
no summary
|
|||||
RFA-NS-22-034 | HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed) | Preclinical and Translational Research in Pain Management | Wed, 02/02/2022 | Sat, 12/07/2024 | Fri, 01/07/2022 |
no summary
|
|||||
OTA-22-002 (PDF, 281K) | EPPIC-Net Pain Research Asset Application (OT2) [ROLLING SUBMISSION ACCEPTED: DATES ARE ESTIMATED] | Clinical Research in Pain Management | Fri, 12/17/2021 | Sun, 12/31/2023 | Fri, 12/17/2021 |
no summary
|
|||||
RFA-NS-21-029 | HEAL Initiative: Planning Studies for Initial Analgesic Development [Small Molecules and Biologics] (R61 Clinical Trial Not Allowed) | Preclinical and Translational Research in Pain Management | Sat, 06/19/2021 | Wed, 10/11/2023 | Tue, 06/08/2021 |
no summary
|
|||||
NOT-NS-21-061 | Notice of Early Termination of RFA-NS-21-016, HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed) | Preclinical and Translational Research in Pain Management | Sat, 06/19/2021 | Wed, 10/11/2023 | Tue, 05/18/2021 |
no summary
|
|||||
PAR-21-183 | Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional) | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Sun, 07/04/2021 | Thu, 12/07/2023 | Tue, 03/23/2021 |
no summary
|
|||||
NOT-NS-20-107 Show Summary |
Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) | Cross-Cutting Research | Sun, 11/15/2020 | Thu, 05/16/2024 | Mon, 10/19/2020 |
Diversity Supplement Guidance pdf 221.15 KB |
|||||
RFA-NS-21-010 | HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) | Preclinical and Translational Research in Pain Management | Sun, 10/18/2020 | Mon, 01/08/2024 | Wed, 09/16/2020 |
no summary
|